Proteomics International Laboratories Ltd
Company Profile
Business description
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials.
Contact
6 Verdun Street
QEII Medical Centre, QQ Block
Nedlands
PerthWA6009
AUST: +61 893891992
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Proteomics International Laboratories Ltd News & Analysis
funds
Proteomics set for growth, says Kardinia
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.10 | 46.00 | 0.51% |
| CAC 40 | 7,853.40 | 48.43 | 0.62% |
| DAX 40 | 24,354.45 | 168.86 | 0.70% |
| Dow JONES (US) | 44,922.27 | 463.66 | 1.04% |
| FTSE 100 | 9,172.37 | 7.14 | 0.08% |
| HKSE | 25,519.32 | 94.35 | -0.37% |
| NASDAQ | 21,713.14 | 31.24 | 0.14% |
| Nikkei 225 | 42,649.26 | 625.41 | -1.45% |
| NZX 50 Index | 12,834.08 | 67.54 | 0.53% |
| S&P 500 | 6,466.58 | 20.82 | 0.32% |
| S&P/ASX 200 | 8,873.80 | 46.70 | 0.53% |
| SSE Composite Index | 3,666.44 | 17.02 | -0.46% |